|
|
|
Volumn 34, Issue 2, 2007, Pages 301-304
|
|
Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE;
4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE;
ANTINEOPLASTIC AGENT;
BCR ABL TYROSINE KINASE;
BCR-ABL TYROSINE KINASE;
DASATINIB;
IMATINIB;
NS 187;
NS-187;
PIPERAZINE DERIVATIVE;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
PYRIMIDINE DERIVATIVE;
THIAZOLE DERIVATIVE;
UNCLASSIFIED DRUG;
ARTICLE;
CHEMISTRY;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
DRUG RESISTANCE;
HUMAN;
PATHOLOGY;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
LEUKEMIA, MYELOID, CHRONIC;
PIPERAZINES;
PROTEIN KINASE INHIBITORS;
PROTEIN-TYROSINE KINASES;
PYRIMIDINES;
THIAZOLES;
|
|
EID: 33947534528
PISSN: 03850684
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|
